Inj imip 4 cilas 4 releb 2mg
Products billed under this code include Recarbrio.
Payment limit per 4 MG-4 MG-2 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Recarbrio.
Payment limit per 4 MG-4 MG-2 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Recarbrio | Merck Sharp & Dohme LLC | 00006-3856-02 | 3125 | $8,425.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2.696 | +$0.005 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted September 17, 2026 |
| 3Q26 | $2.691 | +$0.095 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted September 15, 2026 |
| 2Q26 | $2.596 | −$0.004 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted September 15, 2026 |
| 1Q26 | $2.60 | −$0.007 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted September 15, 2026 |
| 4Q25 | $2.607 | −$0.004 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted September 8, 2026 |
| 3Q25 | $2.611 | +$0.114 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted March 10, 2026 |
| 2Q25 | $2.497 | −$0.002 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted March 10, 2026 |
| 1Q25 | $2.499 | −$0.013 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted December 19, 2025 |
| 4Q24 | $2.512 | −$0.003 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 11, 2025 |
| 3Q24 | $2.515 | +$0.068 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 11, 2025 |
| 2Q24 | $2.447 | −$0.015 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted March 11, 2025 |
| 1Q24 | $2.462 | +$0.002 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted December 19, 2024 |
| 4Q23 | $2.46 | −$0.028 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted October 10, 2024 |
| 3Q23 | $2.488 | +$0.106 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 5, 2024 |
| 2Q23 | $2.382 | −$0.002 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted February 23, 2024 |
| 1Q23 | $2.384 | $0.00 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted December 6, 2023 |
| 4Q22 | $2.384 | +$0.004 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 22, 2023 |
| 3Q22 | $2.38 | +$0.067 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 9, 2023 |
| 2Q22 | $2.313 | −$0.001 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted December 14, 2022 |
| 1Q22 | $2.314 | −$0.009 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 8, 2022 |
| 4Q21 | $2.323 | +$0.02 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 2, 2022 |
| 3Q21 | $2.303 | +$0.052 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted June 2, 2022 |
| 2Q21 | $2.251 | −$0.005 | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted March 1, 2022 |
| 1Q21 | $2.256 | – | 4 MG-4 MG-2 MG | Inj imip 4 cilas 4 releb 2mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.